Daily equity-report by epic research 29-02-2012


Published on

Published in: Business, Economy & Finance
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Daily equity-report by epic research 29-02-2012

  1. 1. Daily Equity Report (29 Feb 2012)Daily market Indian equity markets were up 1.79%. Nifty up 94pts and settle at 5375. Sensex was up 285pts at 17731. Bank Nifty up 412pts at 10626.Global market European markets were in green with FTSE up 9pts at 5925, CAC up 10pts at 3452 and DAX up 30pts at 6880. Dow future up 41pts at 13010. USD Trade Balance came at (-) 48.8B Vs (-) 47.8BFiis & Diis CATAGERY DATE BUY SELL NET FII 28-Feb-2012 2937.55 2209.96 727.59 DII 28-Feb-2012 1283.87 1871.08 -587.21
  2. 2. www.epicresearch.co +919993959693 Daily Nifty Gainers COMPANY CURR.RATE VOL PREV.CL NET CHANGE CHANGE% R Infra 601.80 3456.45 541.20 60.60 11.20 R Power 118.40 7263.25 110.00 8.40 7.64 R Comm 94.30 13896.54 87.85 6.45 7.34 JP Asso 74.90 21083.54 69.95 4.95 7.08 IDFC 140.10 6509.00 131.30 8.80 6.70 Daily Nifty Losers COMPANY CURR.RATE VOL PREV.CL NET CHANGE CHANGE% Cairn 366.85 4170.66 377.95 -11.10 -2.94 TCS 1226.55 1986.74 1252.05 -25.50 -2.04 Wipro 420.25 1285.10 424.80 -4.55 -1.07 BPCL 652.70 660.01 659.65 -6.95 -1.05 ITC 210.70 8765.81 212.30 -1.60 -0.75 NIFTY Daily pivots Pivot R4 R3 R2 R1 PP S1 S2 S3 S4 Nifty 5612 5527 5442 5409 5357 5324 5272 5187 5102 Stock in ban period Stocks to watch  ABGSHIP  TCS  BHEL  SBI  ORCHID CHEM  L&T www.epicresearch.co +919993959693
  3. 3. www.epicresearch.co +919993959693 Nifty Daily Chart Bank Nifty Daily Chart www.epicresearch.co +919993959693
  4. 4. www.epicresearch.co +919993959693 Disclaimer The information and views in this report, our website & all the service we provide are believed to be reliable, but we do not accept any responsibility (or liability) for errors of fact or opinion. Users have the right to choose the product/s that suits them the most. Sincere efforts have been made to present the right investment perspective. The information contained herein is based on analysis and up on sources that we consider reliable. This material is for personal information and based upon it & takes no responsibility The information given herein should be treated as only factor, while making investment decision. The report does not provide individually tailor-made investment advice. Epic research recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. Epic research shall not be responsible for any transaction conducted based on the information given in this report, which is in violation of rules and regulations of NSE and BSE. The share price projections shown are not necessarily indicative of future price performance. The information herein, together with all estimates and forecasts, can change without notice. Analyst or any person related to epic research might be holding positions in the stocks recommended. It is understood that anyone who is browsing through the site has done so at his free will and does not read any views expressed as a recommendation for which either the site or its owners or anyone can be held responsible for . Any surfing and reading of the information is the acceptance of this disclaimer. All Rights Reserved. Investment in equity & bullion market has its own risks. We, however, do not vouch for the accuracy or the completeness thereof. we are not responsible for any loss incurred whatsoever for any financial profits or loss which may arise from the recommendations above epic research does not purport to be an invitation or an offer to buy or sell any financial instrument. Our Clients (Paid Or Unpaid), Any third party or anyone else have no rights to forward or share our calls or SMS or Report or Any Information Provided by us to/with anyone which is received directly or indirectly by them. If found so then Serious Legal Actions can be taken. www.epicresearch.co +919993959693